دورية أكاديمية
High Efficacy and Drug Synergy of HDAC6-Selective Inhibitor NN-429 in Natural Killer (NK)/T-Cell Lymphoma
| العنوان: | High Efficacy and Drug Synergy of HDAC6-Selective Inhibitor NN-429 in Natural Killer (NK)/T-Cell Lymphoma |
|---|---|
| المؤلفون: | Garcha, Harsimran Kaur (University of Toronto), Gunning, Patrick T. (University of Toronto), Seo, Hyuk-Soo (Dana-Farber Cancer Institute / Harvard Medical School), Manaswiyoungkul, Pimyupa (University of Toronto), Sedighi, Abootaleb (University of Toronto), Aung, Myint Myat Khine (University of Veterinary Medicine Vienna), Erdogan, Fettah (University of Toronto), Nawar, Nabanita (University of Toronto), Sorger, Helena (University of Veterinary Medicine Vienna), Moriggl, Richard (University of Veterinary Medicine Vienna), de Araujo, Elvin D. (University of Toronto), Herling, Marco (University of Leipzig), Mustjoki, Satu M (University of Helsinki / Helsinki University Hospital Comprehensive Cancer Center), Neubauer, Heidi A. (University of Veterinary Medicine Vienna), Dhe-Paganon, Sirano (Dana-Farber Cancer Institute / Harvard Medical School), Pölöske, Daniel (University of Veterinary Medicine Vienna), Schönefeldt, Susann (University of Veterinary Medicine Vienna) |
| المصدر: | Pharmaceuticals 15(11) (2022) |
| بيانات النشر: | MDPI |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | T-Cell Lymphoma, Histone Deacetylase Inhibitor, Refinement, Therapy, Tubulin, Cancer, Hdac6, Features, Assay |
| الوصف: | NK/T-cell lymphoma (NKTCL) and γδ T-cell non-Hodgkin lymphomas (γδ T-NHL) are highly aggressive lymphomas that lack rationally designed therapies and rely on repurposed chemotherapeutics from other hematological cancers. Histone deacetylases (HDACs) have been targeted in a range of malignancies, including T-cell lymphomas. This study represents exploratory findings of HDAC6 inhibition in NKTCL and γδ T-NHL through a second-generation inhibitor NN-429. With nanomolar in vitro HDAC6 potency and high in vitro and in cellulo selectivity for HDAC6, NN-429 also exhibited long residence time and improved pharmacokinetic properties in contrast to older generation inhibitors. Following unique selective cytotoxicity towards γδ T-NHL and NKTCL, NN-429 demonstrated a synergistic relationship with the clinical agent etoposide and potential synergies with doxorubicin, cytarabine, and SNS-032 in these disease models, opening an avenue for combination treatment strategies. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| العلاقة: | isPartOf:https://phaidra.vetmeduni.ac.at/o:605Test[Publications / University of Veterinary Medicine Vienna]; https://phaidra.vetmeduni.ac.at/o:1689Test |
| DOI: | 10.3390/ph15111321 |
| الإتاحة: | https://doi.org/10.3390/ph15111321Test https://phaidra.vetmeduni.ac.at/o:1689Test |
| حقوق: | CC BY 4.0 International ; http://creativecommons.org/licenses/by/4.0Test/ |
| رقم الانضمام: | edsbas.A0E9E194 |
| قاعدة البيانات: | BASE |
| DOI: | 10.3390/ph15111321 |
|---|